571 related articles for article (PubMed ID: 17667865)
1. Cardiovascular disease under the influence of excess visceral fat.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
[TBL] [Abstract][Full Text] [Related]
2. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
3. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
5. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
6. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
7. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
Després JP; Lemieux I; Alméras N
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
[TBL] [Abstract][Full Text] [Related]
8. The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology.
Després JP; Cartier A; Côté M; Arsenault BJ
Ann Med; 2008; 40(7):514-23. PubMed ID: 18608131
[TBL] [Abstract][Full Text] [Related]
9. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program.
Borel AL; Nazare JA; Smith J; Alméras N; Tremblay A; Bergeron J; Poirier P; Després JP
Obesity (Silver Spring); 2012 Jun; 20(6):1223-33. PubMed ID: 22262155
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome a widespread threatening condition; risk factors, diagnostic criteria, therapeutic options, prevention and controversies: an overview.
Amihăesei IC; Chelaru L
Rev Med Chir Soc Med Nat Iasi; 2014; 118(4):896-900. PubMed ID: 25581945
[TBL] [Abstract][Full Text] [Related]
11. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
13. Decrease in serum adiponectin levels associated with visceral fat accumulation independent of pubertal stage in children and adolescents.
Medina-Bravo P; Meza-Santibáñez R; Rosas-Fernández P; Galván-Duarte R; Saucedo-García R; Velázquez-López L; Torres-Tamayo M
Arch Med Res; 2011 Feb; 42(2):115-21. PubMed ID: 21565624
[TBL] [Abstract][Full Text] [Related]
14. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors.
Quijada Z; Paoli M; Zerpa Y; Camacho N; Cichetti R; Villarroel V; Arata-Bellabarba G; Lanes R
Pediatr Diabetes; 2008 Oct; 9(5):464-71. PubMed ID: 18507788
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome.
O'Gorman CS; Syme C; Lang J; Bradley TJ; Wells GD; Hamilton JK
Clin Endocrinol (Oxf); 2013 Jun; 78(6):907-13. PubMed ID: 23106295
[TBL] [Abstract][Full Text] [Related]
16. Visceral adipose tissue accumulation and cardiovascular disease risk profile in postmenopausal women with impaired glucose tolerance or type 2 diabetes.
Lemieux S; Bédard A; Piché MÈ; Weisnagel SJ; Corneau L; Bergeron J
Clin Endocrinol (Oxf); 2011 Mar; 74(3):340-5. PubMed ID: 21092050
[TBL] [Abstract][Full Text] [Related]
17. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
20. [Risk factors associated with obesity: a metabolic perspective].
Després JP; Pascot A; Lemieux I
Ann Endocrinol (Paris); 2000 Dec; 61 Suppl 6():31-38. PubMed ID: 11148334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
